CASE REPORT: Multidrug-resistant Pseudomonas keratitis and sequential endophthalmitis treated with chlorhexidine and piperacillin-tazobactam

Author:

Lu Louisa1,Shen Alice1,DeBoer Charles1,Mahajan Vinit12,Lin Charles1,Rose-Nussbaumer Jennifer1

Affiliation:

1. Stanford University

2. VA Palo Alto Health Care System

Abstract

Purpose To report the clinical course and treatment strategies employed in management of a case of multidrug-resistant Pseudomonas aeruginosa keratitis progressing to endophthalmitis. The drug-resistant strain was later traced to use of contaminated EzriCare Artificial Tears in a multi-state cluster outbreak. Observations A 57-year-old male patient with a history of Descemet stripping automated endothelial keratoplasty was referred for a culture-positive Pseudomonas corneal ulcer in the right eye that had been treated with several weeks of topical moxifloxacin, fortified vancomycin and tobramycin, and intravitreal injections for endophthalmitis. His cornea was cultured off of antibiotics and grew only rare Propionibacterium acnes. Topical antibiotics and steroids were reduced, but his condition rapidly deteriorated with leading to corneal melt, perforation, and endophthalmitis. Repeat corneal cultures and sensitivity analyses revealed growth of a strain of Pseudomonas aeruginosa that was resistant to fluoroquinolones, aminoglycosides, cephalosporins, monobactams, and carbapenems, and only intermediate susceptibility to piperacillin-tazobactam. The patient underwent a therapeutic penetrating keratoplasty and was subsequently initiated on an intensive regimen of topical chlorhexidine and polymyxin-B/trimethoprim. He also underwent a pars plana vitrectomy with anterior chamber washout, followed by serial injections of intravitreal piperacillin-tazobactam at a dose of 225 mg/0.1 mL. After 8 weeks of intensive treatment, there was gradual with healing of his ocular surface, regression of his hypopyon and posterior inflammation, and no signs of recurrent infection. A public health investigation ultimately revealed that his infection was one of several cases involved in a multistate cluster outbreak of extensively drug-resistant Pseudomonas ocular infections that were traced to the use of contaminated EzriCare Artificial Tears. Conclusions and Importance Multidrug-resistant keratitis and endophthalmitis caused by multidrug-resistant Pseudomonas keratitis requires consideration of nonconventional antimicrobial agents and experimental therapeutic alternatives. Topical chlorhexidine and intravitreal piperacillin-tazobactam are currently nonconventional therapies in the context of bacterial keratitis and endophthalmitis, but were safe and effective in the management of multidrug-resistant Pseudomonas aeruginosa ocular infection.

Publisher

EuCornea

Subject

Electrical and Electronic Engineering,Building and Construction

Reference21 articles.

1. Update: Multistate Cluster of VIM- and GES-producing Carbapenemresistant Pseudomonas aeruginosa associated with Artificial Tears;American Academy of Ophthalmology,2023

2. A Comparison of Topical Chlorhexidine, Ciprofloxacin, and Fortified Tobramycin/Cefazolin in Rabbit Models ofStaphylococcusandPseudomonasKeratitis;Ping Bu;Journal of Ocular Pharmacology and Therapeutics: The Official Journal of the Association for Ocular Pharmacology and Therapeutics,2007

3. Molecular mechanisms of fluoroquinolone resistance;Feng-Jui Chen;Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi,2003

4. Acanthamoeba keratitis: diagnosis and treatment update 2009;John K.G. Dart;American Journal of Ophthalmology,2009

5. Emerging Moxifloxacin Resistance in Pseudomonas aeruginosa Keratitis Isolates in South India;Catherine E. Oldenburg;Ophthalmic Epidemiology,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3